IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Waelbroeck	Art Unit:	3624
Application No.	10/603,100	Examiner:	
Filed:	Jun 24, 2003	Confirmation No.	1663
		Attorney Docket No.	061165-0011
Title:	CONFIDENTIAI METHOD	L BLOCK TRADING	

INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450,

Sir:

itent a	informa applicati	tion whi on. It is	with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided ich the Examiner may consider material to the examination of the subject U.S. requested that the Examiner make this information of record if it is deemed tion of the application.		
	Enclosures accompanying this Information Disclosure Statement are:				
	la.⊠	 A list of all patents, publications, applications, or other information submitted for consideration by the office (PTO Form 1449). 			
	1 b . 🗆	A legible copy of:			
			Each U.S. patent application publication and U.S. and foreign patent;		
			Each publication or that portion which caused it to be listed on the PTO-1449;		
			For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;		
			all other information or portion which caused it to be listed on the PTO-1449.		
	1c. 🗆	An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.			

		1 d . 🗆	$\label{prop:eq:explanations} Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.$
2.		This In	formation Disclosure Statement is filed under 37 C.F.R. §1.97(b):
		2a. □	Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
		2b. □	Within three months of the date of entry of the national stage as set forth in $\S1.491$ in an international application;
		2c. 🗆	Before the mailing of the first Office action on the merits;
		2d. □	Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3.	×	in 37 C	formation Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the tion.
			(Check either Item 3a or 3b)
		3a. ⊠	The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
		3Ь. □	The \$180.00 fee set forth in 37 C.F.R. $\S1.17(p)$ in accordance with 37 C.F.R. $\S1.97(c)$ is:
			□ enclosed □ to be charged to Morgan Lewis & Bockius LLP Deposit Account No. 50-0310. (Item 3b to be checked if any reference known for more than 3 months)
1.			formation Disclosure Statement is filed under 37 C.F.R. $\S1.97(d)$ after the period specified .F.R. $\S1.97(c)$, but on or before the date of payment of the issue fee.
		The \$1	80.00 fee set forth in 37 C.F.R. §1.17(i)(1) is:
			 □ enclosed. □ to be charged to Morgan Lewis & Bockius LLP Deposit Account No. 50-0310.
		The Ce	rtification Statement in Item 5 below is applicable.
5.	X	Certific	eation Statement (applicable if Item 3a or Item 4 is checked)
			(Check either Item 5a or 5b)
		5a. ⊠	In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

I-NY/2243699 1 - 2 -

		5b. □	In accordance with 37 C.F.R. §1.97(e)(2), it is certified that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was known by any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.		
		5c. □	Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by an individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement.		
6.		This ap	oplication is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).		
	(Check appropriate Items 6a, 6b and/or 6c)				
		6a. 🗆	A Petition to Withdraw from issue under 37 C.F.R. $\S1.313(b)(5)$ is concurrently filed herewith.		
		6b. □	Copies of publications listed on Form PTO-1449 from prior application Serial No, filed on, of which this application claims priority under 35 U.S.C. $\S120$, are not being submitted pursuant to 37 C.F.R. $\S1.98(d)$.		
		6c. 🗆	Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.		
7.		This is	a Supplemental Information Disclosure Statement. (Check either Item 7a or 7b)		
		7a. □	This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on		
		7b. □	This Supplemental Information Disclosure Statement is timely filed within one (1) month of a PTO Notice under 37 C.F.R. $\S1.97(i).$		
8.			rdance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be evance of each non-English language publication is:		
(Check Item 8a, 8b, or 8c)					
		8a. □	satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.		

I-NY/2243699 1 - 3 -

8b. □ set forth in the application.
8c. □ enclosed as an attachment hereto.

Date: November 5, 2007

- ☑ The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Morgan Lewis & Bockius LLP Deposit Account No. 50-0310.
- 10.
 No admission is made that the information cited in this Statement is, or is considered to be, material to patentability, nor is this a representation that a search has been made (unless a search report for a foreign counterpart application or PCT International Search Report is submitted herewith). 37 C.F.R. §81.97(g) and (h).

Respectfully submitted,

Pristine S. Johannessen (Reg. No. 55,302)

MORGAN, LEWIS & BOCKIUS LLP 1111 Pennsylvania Ave., N.W. Washington, DC 20004

(212) 309 6632

Customer Number No. 09626

1-NY/2243699 1 - 4 -